Why Is Amkor Stock Up So Much?
Semiconductor packaging and testing major Amkor (NASDAQ:AMKR) has started 2026…
Buy
64
SBHMY Quote, Financials, Valuation and Earnings
Last price:
$18.22
Seasonality move
:
-3.63%
Day range:
$18.22 - $18.22
52-week range:
$7.15 - $20.16
Dividend yield:
1.26%
P/E ratio:
31.84x
P/S ratio:
3.87x
P/B ratio:
4.29x
Volume:
--
Avg. volume:
22
1-year change:
130.85%
Market cap:
$16.3B
Revenue:
$4B
EPS (TTM):
$0.60
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SBHMY
Sino Biopharmaceutical Ltd.
|
-- | -- | -- | -- | -- |
|
HCM
HUTCHMED (China) Ltd.
|
-- | -- | -- | -- | $22.38 |
|
HKPD
Cellyan Biotechnology Ltd.
|
-- | -- | -- | -- | -- |
|
PRE
Prenetics Global Ltd.
|
$45.9M | -- | 265.18% | -- | $26.00 |
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SBHMY
Sino Biopharmaceutical Ltd.
|
$18.22 | -- | $16.3B | 31.84x | $0.13 | 1.26% | 3.87x |
|
HCM
HUTCHMED (China) Ltd.
|
$14.72 | $22.38 | $2.5B | 4.92x | $0.00 | 0% | 4.25x |
|
HKPD
Cellyan Biotechnology Ltd.
|
$0.78 | -- | $8.5M | 8.18x | $0.00 | 0% | 0.75x |
|
PRE
Prenetics Global Ltd.
|
$15.53 | $26.00 | $261.3M | -- | $0.00 | 0% | 3.02x |
|
RGC
Regencell Bioscience Holdings Ltd.
|
$45.79 | -- | $22.6B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SBHMY
Sino Biopharmaceutical Ltd.
|
23.1% | -0.664 | -- | 1.14x |
|
HCM
HUTCHMED (China) Ltd.
|
7.07% | 0.158 | -- | 4.41x |
|
HKPD
Cellyan Biotechnology Ltd.
|
-- | 0.000 | -- | -- |
|
PRE
Prenetics Global Ltd.
|
1.29% | 5.284 | 1.18% | 1.01x |
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | 18.151 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SBHMY
Sino Biopharmaceutical Ltd.
|
-- | -- | 6.83% | 8.57% | -- | -- |
|
HCM
HUTCHMED (China) Ltd.
|
-- | -- | 46.32% | 50.64% | -- | -- |
|
HKPD
Cellyan Biotechnology Ltd.
|
-- | -- | -- | -- | -- | -- |
|
PRE
Prenetics Global Ltd.
|
$14M | -$6.6M | -26.04% | -26.74% | -27.85% | -- |
|
RGC
Regencell Bioscience Holdings Ltd.
|
-- | -- | -- | -- | -- | -- |
Sino Biopharmaceutical Ltd. vs. Competitors
-
Which has Higher Returns SBHMY or HCM?
HUTCHMED (China) Ltd. has a net margin of -- compared to Sino Biopharmaceutical Ltd.'s net margin of --. Sino Biopharmaceutical Ltd.'s return on equity of 8.57% beat HUTCHMED (China) Ltd.'s return on equity of 50.64%.
Company Gross Margin Earnings Per Share Invested Capital SBHMYSino Biopharmaceutical Ltd.-- -- $7.2B HCMHUTCHMED (China) Ltd.-- -- $1.3B -
What do Analysts Say About SBHMY or HCM?
Sino Biopharmaceutical Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand HUTCHMED (China) Ltd. has an analysts' consensus of $22.38 which suggests that it could grow by 52.07%. Given that HUTCHMED (China) Ltd. has higher upside potential than Sino Biopharmaceutical Ltd., analysts believe HUTCHMED (China) Ltd. is more attractive than Sino Biopharmaceutical Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SBHMYSino Biopharmaceutical Ltd.0 0 0 HCMHUTCHMED (China) Ltd.9 2 1 -
Is SBHMY or HCM More Risky?
Sino Biopharmaceutical Ltd. has a beta of 0.590, which suggesting that the stock is 40.969% less volatile than S&P 500. In comparison HUTCHMED (China) Ltd. has a beta of 0.418, suggesting its less volatile than the S&P 500 by 58.206%.
-
Which is a Better Dividend Stock SBHMY or HCM?
Sino Biopharmaceutical Ltd. has a quarterly dividend of $0.13 per share corresponding to a yield of 1.26%. HUTCHMED (China) Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sino Biopharmaceutical Ltd. pays 55.99% of its earnings as a dividend. HUTCHMED (China) Ltd. pays out -- of its earnings as a dividend. Sino Biopharmaceutical Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SBHMY or HCM?
Sino Biopharmaceutical Ltd. quarterly revenues are --, which are smaller than HUTCHMED (China) Ltd. quarterly revenues of --. Sino Biopharmaceutical Ltd.'s net income of -- is lower than HUTCHMED (China) Ltd.'s net income of --. Notably, Sino Biopharmaceutical Ltd.'s price-to-earnings ratio is 31.84x while HUTCHMED (China) Ltd.'s PE ratio is 4.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sino Biopharmaceutical Ltd. is 3.87x versus 4.25x for HUTCHMED (China) Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SBHMYSino Biopharmaceutical Ltd.3.87x 31.84x -- -- HCMHUTCHMED (China) Ltd.4.25x 4.92x -- --
-
Which has Higher Returns SBHMY or HKPD?
Cellyan Biotechnology Ltd. has a net margin of -- compared to Sino Biopharmaceutical Ltd.'s net margin of --. Sino Biopharmaceutical Ltd.'s return on equity of 8.57% beat Cellyan Biotechnology Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SBHMYSino Biopharmaceutical Ltd.-- -- $7.2B HKPDCellyan Biotechnology Ltd.-- -- -- -
What do Analysts Say About SBHMY or HKPD?
Sino Biopharmaceutical Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Cellyan Biotechnology Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Sino Biopharmaceutical Ltd. has higher upside potential than Cellyan Biotechnology Ltd., analysts believe Sino Biopharmaceutical Ltd. is more attractive than Cellyan Biotechnology Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SBHMYSino Biopharmaceutical Ltd.0 0 0 HKPDCellyan Biotechnology Ltd.0 0 0 -
Is SBHMY or HKPD More Risky?
Sino Biopharmaceutical Ltd. has a beta of 0.590, which suggesting that the stock is 40.969% less volatile than S&P 500. In comparison Cellyan Biotechnology Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SBHMY or HKPD?
Sino Biopharmaceutical Ltd. has a quarterly dividend of $0.13 per share corresponding to a yield of 1.26%. Cellyan Biotechnology Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sino Biopharmaceutical Ltd. pays 55.99% of its earnings as a dividend. Cellyan Biotechnology Ltd. pays out -- of its earnings as a dividend. Sino Biopharmaceutical Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SBHMY or HKPD?
Sino Biopharmaceutical Ltd. quarterly revenues are --, which are smaller than Cellyan Biotechnology Ltd. quarterly revenues of --. Sino Biopharmaceutical Ltd.'s net income of -- is lower than Cellyan Biotechnology Ltd.'s net income of --. Notably, Sino Biopharmaceutical Ltd.'s price-to-earnings ratio is 31.84x while Cellyan Biotechnology Ltd.'s PE ratio is 8.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sino Biopharmaceutical Ltd. is 3.87x versus 0.75x for Cellyan Biotechnology Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SBHMYSino Biopharmaceutical Ltd.3.87x 31.84x -- -- HKPDCellyan Biotechnology Ltd.0.75x 8.18x -- --
-
Which has Higher Returns SBHMY or PRE?
Prenetics Global Ltd. has a net margin of -- compared to Sino Biopharmaceutical Ltd.'s net margin of -28.82%. Sino Biopharmaceutical Ltd.'s return on equity of 8.57% beat Prenetics Global Ltd.'s return on equity of -26.74%.
Company Gross Margin Earnings Per Share Invested Capital SBHMYSino Biopharmaceutical Ltd.-- -- $7.2B PREPrenetics Global Ltd.59.54% -$0.53 $163.3M -
What do Analysts Say About SBHMY or PRE?
Sino Biopharmaceutical Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Prenetics Global Ltd. has an analysts' consensus of $26.00 which suggests that it could grow by 99.61%. Given that Prenetics Global Ltd. has higher upside potential than Sino Biopharmaceutical Ltd., analysts believe Prenetics Global Ltd. is more attractive than Sino Biopharmaceutical Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SBHMYSino Biopharmaceutical Ltd.0 0 0 PREPrenetics Global Ltd.1 0 0 -
Is SBHMY or PRE More Risky?
Sino Biopharmaceutical Ltd. has a beta of 0.590, which suggesting that the stock is 40.969% less volatile than S&P 500. In comparison Prenetics Global Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SBHMY or PRE?
Sino Biopharmaceutical Ltd. has a quarterly dividend of $0.13 per share corresponding to a yield of 1.26%. Prenetics Global Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sino Biopharmaceutical Ltd. pays 55.99% of its earnings as a dividend. Prenetics Global Ltd. pays out -- of its earnings as a dividend. Sino Biopharmaceutical Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SBHMY or PRE?
Sino Biopharmaceutical Ltd. quarterly revenues are --, which are smaller than Prenetics Global Ltd. quarterly revenues of $23.6M. Sino Biopharmaceutical Ltd.'s net income of -- is lower than Prenetics Global Ltd.'s net income of -$6.8M. Notably, Sino Biopharmaceutical Ltd.'s price-to-earnings ratio is 31.84x while Prenetics Global Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sino Biopharmaceutical Ltd. is 3.87x versus 3.02x for Prenetics Global Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SBHMYSino Biopharmaceutical Ltd.3.87x 31.84x -- -- PREPrenetics Global Ltd.3.02x -- $23.6M -$6.8M
-
Which has Higher Returns SBHMY or RGC?
Regencell Bioscience Holdings Ltd. has a net margin of -- compared to Sino Biopharmaceutical Ltd.'s net margin of --. Sino Biopharmaceutical Ltd.'s return on equity of 8.57% beat Regencell Bioscience Holdings Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SBHMYSino Biopharmaceutical Ltd.-- -- $7.2B RGCRegencell Bioscience Holdings Ltd.-- -- -- -
What do Analysts Say About SBHMY or RGC?
Sino Biopharmaceutical Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Regencell Bioscience Holdings Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Sino Biopharmaceutical Ltd. has higher upside potential than Regencell Bioscience Holdings Ltd., analysts believe Sino Biopharmaceutical Ltd. is more attractive than Regencell Bioscience Holdings Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SBHMYSino Biopharmaceutical Ltd.0 0 0 RGCRegencell Bioscience Holdings Ltd.0 0 0 -
Is SBHMY or RGC More Risky?
Sino Biopharmaceutical Ltd. has a beta of 0.590, which suggesting that the stock is 40.969% less volatile than S&P 500. In comparison Regencell Bioscience Holdings Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SBHMY or RGC?
Sino Biopharmaceutical Ltd. has a quarterly dividend of $0.13 per share corresponding to a yield of 1.26%. Regencell Bioscience Holdings Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sino Biopharmaceutical Ltd. pays 55.99% of its earnings as a dividend. Regencell Bioscience Holdings Ltd. pays out -- of its earnings as a dividend. Sino Biopharmaceutical Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SBHMY or RGC?
Sino Biopharmaceutical Ltd. quarterly revenues are --, which are smaller than Regencell Bioscience Holdings Ltd. quarterly revenues of --. Sino Biopharmaceutical Ltd.'s net income of -- is lower than Regencell Bioscience Holdings Ltd.'s net income of --. Notably, Sino Biopharmaceutical Ltd.'s price-to-earnings ratio is 31.84x while Regencell Bioscience Holdings Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sino Biopharmaceutical Ltd. is 3.87x versus -- for Regencell Bioscience Holdings Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SBHMYSino Biopharmaceutical Ltd.3.87x 31.84x -- -- RGCRegencell Bioscience Holdings Ltd.-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Shopify Stock a Good Buy Now?
eCommerce technology platform Shopify (NASDAQ:SHOP) delivered impressive returns in 2025…
Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
